Print

IVIg No Help in Neonatal Blood Disease, Leiden University Medical Center Study Finds  
3/21/2011 6:32:29 AM

MedPageToday -- Prophylactic treatment with intravenous immunoglobulin (IVIg) failed to show benefits in neonatal rhesus hemolytic disease, according to results from a randomized controlled trial. There was no difference in the rate of exchange transfusions among infants who received IVIg and controls (17% versus 15%, P=0.99), reported Vivianne E.H.J. Smits-Wintjens, MD, of Leiden University in the Netherlands, and colleagues.
//-->